641 results on '"Seghatchian, Jerard"'
Search Results
2. Hematological toxicities of immune checkpoint inhibitors and the impact of blood transfusion and its microbiome on therapeutic efficacy and recipient’s safety and survival outcome:A systematic narrative appraisal of where we are now!
3. Cryopreservation of apheresis platelets treated with riboflavin and UV light
4. Autoimmune complications of COVID-19 and potential consequences for long-lasting disease syndromes
5. Blood transfusion in autoimmune rheumatic diseases
6. Spotlights on the latest opinions on identification, prevention, and management of newer CoV-2 variants: A roundup appraisal on innovative ideas and designer vaccines for Omicron
7. Editorial commentary
8. SARS-CoV-2 and cancer: the intriguing and informative cross-talk
9. Platelet and extracellular vesicles in COVID-19 infection and its vaccines
10. Therapeutic Use of Convalescent Plasma in COVID-19 Infected Patients with Concomitant Hematological Disorders
11. Assessment of extracellular vesicles using IFC for application in transfusion medicine
12. Trends and targets of various types of stem cell derived transfusable RBC substitution therapy: Obstacles that need to be converted to opportunity
13. An Overview of Current Position on Cell Therapy in Transfusion Science and Medicine: From Fictional Promises to Factual and Perspectives from Red Cell Substitution to Stem Cell Therapy
14. Update on newer approaches to prevent or treat COVID-19 infection: What we all need the most right now!!
15. An update on COVID-19 infection control measures, plasma-based therapeutics, corticosteroid pharmacotherapy and vaccine research
16. In vitro platelet production for transfusion purposes: Where are we now?
17. Spotlight on the current perspectives on applications of human blood cell culture and organoids: Introductory remarks
18. Cell culture – Fact and fiction
19. Covid-19, induced activation of hemostasis, and immune reactions: Can an auto-immune reaction contribute to the delayed severe complications observed in some patients?
20. When I need you most: frozen red blood cells for transfusion
21. Optimizing the supply of whole blood-derived bioproducts through the combined implementation of cryopreservation and pathogen reduction technologies and practices: An overview
22. Poor economics - Transforming challenges in transfusion medicine and science into opportunities
23. Platelet-derived bio-products: Classification update, applications, concerns and new perspectives
24. Plasma fractionation in countries with limited infrastructure and low-/medium income: How to move forward?
25. Vitamin B12 deficiency and metabolism-mediated thrombotic microangiopathy (MM-TMA)
26. Editorial commentary – A snapshot on the role of newer technologies identifying variability in donor red cell storage stability and its implications on recipients’ clinical outcome
27. An invite for evidence-based insights and expert viewpoints on blood donor recruitment and retention
28. Platelet rich plasma in treatment of musculoskeletal pathologies
29. Viral safety of human platelet lysate for cell therapy and regenerative medicine: Moving forward, yes, but without forgetting the past
30. Spotlight on the impact of transfusion support, the detrimental influence of blood donation microbiomes on hematological immune-related toxicities, and the sustained efficacy and survival outcomes of immune checkpoint inhibitors’ treated cancer patients
31. T-cell lymphocytopenia: an omnipresent predictor of morbidity and mortality in consequence of SARS-CoV disease and influenza A infections
32. Spotlight on SARS CoV-2 infection inducing autoimmunity, through the formation of autoantibody to self hemostatic components or to host cells, often leading to severe thrombotic or bleeding events
33. Spotlight on the impacts of transfusion on patients with Autoimmune Rheumatic Diseases
34. Autoimmune complications of COVID-19 and potential consequences for long-lasting disease syndromes
35. Do highly transmissible omicron subtypes BA.4/BA.5 have any impact on the HLA class I /II antibodies of apheresis donors, and could mucosal omicron-specific vaccines prevent transmissibility and provide more durable protection?
36. Cryopreservation of apheresis platelets treated with riboflavin and UV light
37. Editorial: Time to explore the missing links: the cross-talk between COVID infection and cancer cells; lingering questions on the longitudinal efficacy of the front line immunotherapies against unpredictable “Omicron ghosts” and insights from CAR-T cell therapy pointing toward better clinical outcomes
38. What’s Is Happening Section [Trasci.61.3]
39. Editorial comments: Looking for some innovative diagnostic or developmental research studies that might influence our laboratory and clinical decision-making
40. An all-round appraisal of the latest viewpoints on “Acute Thrombotic Coagulability” and an update on the “inflammation-conditioned” profiles of platelets in sepsis patients
41. An appraisal of the latest achievements on platelet lysate designed for clinical opportunities in regenerative medicine and cellular therapy
42. Leukocyte-reduced blood components: laboratory and clinical aspects
43. Spotlights on “Process Capability Index Trends”: A new development in the manufacturing of blood components and related industries
44. Spotlight on the latest trends on CoV-2 Alpha and Delta variants in the UK; Targeting blood donor population for assessing the effect of the mRNA vaccines on the seroprevalence of CoV-2 Delta variant antibodies and reflections on the management of alloimmunisation in transfused patients with constitutional anaemias in Norway
45. Back to basics on assessment of extracellular vesicle activity states, using modern captured based assays, combined with innovative IFC and proteomics, that might become tomorrow’s realities
46. Exploratory spotlights on the proteome of extracellular vesicles in red blood cell units prepared by the same donors revealed that leukoreduction may matter for the quality and safety of transfusion therapy: Back to basics for research topics that might begin tomorrow’s realities
47. What’s happening CAR T cell immunotherapy
48. Facts and challenges on global deployment of vaccines for the immunotherapy of the evolving SARS Cov-2 variants: What a new year, with a fast spreading South African and the most fearful Brazilian variants, as the unwanted gifts, imposing enormous crises to surmount
49. Polycythaemia vera: molecular genetics, diagnostics and therapeutics
50. New generation of vaccines and convalescent plasma therapy for management of CoV-2: Perspectives from the UK and potential deployment in the current global pandemic
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.